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Viewpoint
Since 1995, the African Programme for
Onchocerciasis Control (APOC) has coor-
dinated mass treatment with ivermectin in
16 sub-Saharan countries (Angola, Bur-
undi, Cameroon, Central African Repub-
lic, Chad, Congo, Democratic Republic of
Congo, Equatorial Guinea, Ethiopia, Li-
beria, Malawi, Nigeria, North Sudan,
South Sudan, Uganda, and the United
Republic of Tanzania) with the aim to
control morbidity due to infection with
Onchocerca volvulus, a filarial nematode.
Recently, we predicted trends in preva-
lence of infection, visual impairment,
blindness, and troublesome itch due to
onchocerciasis in APOC countries for the
period 1995–2015, based on extensive
data on pre-control infection levels, pop-
ulation coverage of ivermectin mass treat-
ment, and the association between infec-
tion and morbidity [1]. We also estimated
the associated health impact, expressed in
disability-adjusted life years (DALYs).
However, the estimated health impact
was based on disability weights from the
2004 update of the Global Burden of
Disease (GBD) study [2], which have been
criticized for being based solely on the
opinions of health professionals [3,4]. The
recently published GBD 2010 study ad-
dressed this criticism by providing updated
disability weights based on household
surveys in Bangladesh, Indonesia, Peru,
and Tanzania, an open internet survey,
and a telephone survey in the United
States [5]. As a result of this population-
based approach, the disability weights for
visual impairment, blindness, and trouble-
some itch have changed considerably and
should better reflect our ideas and beliefs
as a society of what constitutes health. For
future reference, we provide an updated
estimate of the health impact of APOC
activities, based on previously predicted
trends in averted number of cases with
infection and morbidity, but using updated
disability weights for visual impairment,
blindness, and troublesome itch.
Identical to previously used methods
[1], we calculated the health impact of
APOC for each year between 1995 and
2015, expressed in DALYs averted. The
DALY metric is the sum of years of life lost
(YLL) due to premature mortality (from
blindness) and years lived in disability
(YLD), weighted by a disability weight
representing the loss of quality of life [5].
DALYs averted were calculated as the
difference between two scenarios: a factual
scenario in which APOC activities have
taken place as documented, and a coun-
terfactual scenario in which APOC activ-
ities have not taken place at all, effectively
translating to DALYaverted~DYLLblindness
z DYLDblindnesszDYLDvisual impairmentz
DYLDitch. Here, DYLLblindness is the
averted number of YLL related to prema-
ture mortality from blindness (as previous-
ly estimated [1]), and DYLDx is the
averted number of YLD due to symptom
x. Averted YLD were calculated as
DYLDx~DNx:dwx, where DNx is the
averted number of person-years of symp-
tom x (i.e., difference in annually prevalent
cases between the factual and counterfac-
tual scenarios, as previously estimated [1]),
and dwx is the associated updated disabil-
ity weight, derived from the GBD 2010
study [5].
Compared to previous disability weights
[2], updated weights were considerably
lower for visual impairment (0.033, previ-
ously 0.282) and blindness (0.195, previ-
ously 0.594), reflecting that the loss in
quality of life because of these manifesta-
tions is considerably lower than previously
assumed. On the contrary, the disability
weight for troublesome itch has increased
(0.108, previously 0.068). The disability
weight for visual impairment represents
‘‘moderate visual impairment’’ in the
GBD 2010 study. The updated disability
weights do not include a category for itch
alone. Hence the disability weight for
troublesome itch was derived from a
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generic class of disability weights for
‘‘disfigurement with itch or pain.’’ This
class consists of three severity levels,
characterized as ‘‘causing some worry
and discomfort’’ (disability weight 0.029),
‘‘a person having trouble concentrating
and sleeping’’ (disability weight 0.187),
and ‘‘causing a person to avoid social
contact, feel worried, sleep poorly, and
think about suicide’’ (disability weight
0.562). Based on original precontrol data
from a previously published, multicountry
study [6] (excluding data from Ghana and
Cameroon, which were collected based on
convenience sampling rather than house-
hold surveys), we assumed that onchocer-
cal itch regularly causes insomnia in about
half of the cases and, therefore, calculated
YLD due to itch using the mean of the
disability weights for the first two severity
levels (0.108). We assumed that this
disability weight also applies during iver-
mectin mass treatment, even though the
fraction of insomniacs among cases of itch
might decrease with repeated mass treat-
ments (due to lower infection loads and
consequent lower severity of itch). Unfor-
tunately, previous studies on trends of
onchocercal itch during ivermectin mass
treatment do not report on insomnia [7,8].
Therefore, if anything, we may be under-
estimating the impact of ivermectin mass
treatment on the burden of itch (and the
associated DALYs averted).
Figure 1 illustrates trends in DALYs
lost due to troublesome itch, visual
impairment, and blindness, and DALYs
averted by APOC. Table 1 gives more
detailed information on the number of
prevalent cases (according to the factual
scenario) and DALYs lost and averted per
year. For onchocercal visual impairment
and blindness, the updated estimates of
the averted burden turned out lower than
the previous estimates. In contrast, for
troublesome itch, the updated estimate of
the burden averted turned out higher
than the previous estimate. For visual
impairment and troublesome itch, the
difference between previous and updated
estimates was proportional to the change
in values of the associated disability
weights. For blindness, however, this
difference was not proportional, as the
burden of blindness also included years of
life lost due to premature mortality (which
is exactly the same for previous and
updated estimates).
Overall, we estimated that APOC has
cumulatively averted 8.9 million DALYs
due to onchocerciasis through 2010, and
will avert another 10.1 million DALYs
between 2011 and 2015, adding up to a
total of 19.0 million DALYs averted
through 2015. These updated estimates
do not differ much from previous estimates
(8.2 million DALYs averted through 2010,
and another 9.2 million between 2011 and
2025). In relative terms, the burden of
onchocerciasis in APOC areas has de-
creased from 23.1 DALYs per 1,000
persons in 1995 to 8.6 DALYs per 1,000
persons in 2010, and is expected to further
decrease to 3.7 DALYs per 1,000 persons
in 2015.
The updated disability weights provided
by the GBD 2010 study are based on
population surveys rather than expert
opinion. Therefore, they are presumably
less subjective and should better reflect our
ideas and beliefs as a society of what
constitutes health than previous disability
weights [5]. However, it has been argued
that the disability weights for visual impair-
Figure 1. Disability-adjusted life years (DALYs) lost due to onchocerciasis from 1995 to 2015. The total height of the bars (colored plus
blank) represents the estimated number of DALYs lost in a counterfactual scenario without ivermectin mass treatment (increasing trend due to
population growth). The colored part of each bar represents the estimated actual number of DALYs lost (declining trend due to ivermectin mass
treatment). The blank part of each bar therefore represents the annual number of DALYs averted by ivermectin mass treatment in the total APOC
population.
doi:10.1371/journal.pntd.0002759.g001
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ment and blindness underestimate the
burden of vision loss in rural Africa
[9,10]. One of the main arguments is that
the surveys used to establish new disability
weights did not adequately cover rural
Africa (Tanzania only). Furthermore, being
strictly a metric of health loss rather than
wellbeing [5], DALYs do not capture the
effects of vision loss and skin disease on
socioeconomic status [11] and productivity
[12,13]. Therefore, the impact of APOC
most likely encompasses more than what
we report here in terms of health impact.
According to our updated estimates,
skin disease is now the most important
contributor to the burden of onchocer-
ciasis, rather than eye disease. More-
over, the true disease burden of oncho-
cercal skin disease (and the burden
averted by APOC) is still larger than
we estimate here, as our updated esti-
mates do not include disfiguring skin
disease, or other sequelae potentially
associated with onchocerciasis, such as
epilepsy [14] and head-nodding syn-
drome [15]. The additional burden of
disfiguring skin disease is probably
considerable, given the relatively high
values of the updated disability weights
for disfiguring skin disease and the high
precontrol prevalence of disfiguring skin
disease in areas endemic for onchocer-
ciasis [6]. This underlines the impor-
tance of onchocercal skin disease, espe-
cially in forest areas where vision loss is
relatively rare [16].
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